Related Experiment Videos
High density lipoprotein complexes as delivery vehicles for anticancer drugs
Andras G Lacko1, Maya Nair, Sulabha Paranjape
1Institute for Cancer Research, Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth 76107, USA. alacko@hsc.unt.edu
Anticancer Research
|August 15, 2002
Summary
Recombinant high density lipoprotein (rHDL) particles efficiently delivered the anticancer drug taxol to cancer cells. This targeted delivery via HDL core components may reduce chemotherapy side effects.
Area of Science:
- Biochemistry
- Nanotechnology
- Oncology
Background:
- High-density lipoprotein (HDL) nanoparticles offer potential for targeted drug delivery.
- Incorporating therapeutic agents into HDL structures requires precise formulation.
Purpose of the Study:
- To develop and evaluate recombinant HDL (rHDL) particles as drug delivery vehicles for the anticancer drug taxol.
- To assess the uptake of rHDL-taxol complexes by cancer cells.
Main Methods:
- Preparation of rHDL particles with defined composition (phosphatidylcholine, apolipoprotein A-1, cholesterol, cholesteryl esters).
- Incorporation of three taxol molecules per rHDL particle.
- Evaluation of cellular uptake by various cancer cell lines and control cells (HGL5).
- Immunoblotting using scavenger receptor B1 (SR-B1) antibody.
Main Results:
- rHDL particles were successfully prepared with a molecular weight of approximately 187,000 kdaltons.
- Cancer cell lines demonstrated efficient uptake of cholesteryl ester and taxol from rHDL complexes.
- Strong immunoreactivity with the SR-B1 antibody was observed in several cancer cell lines, suggesting receptor-mediated uptake.
Conclusions:
- rHDL complexes serve as effective drug delivery vehicles due to cancer cells' ability to acquire HDL core components.
- Targeting anticancer drugs within rHDL complexes can potentially minimize toxic side effects associated with chemotherapy.
- The scavenger receptor B1 (SR-B1) may play a role in the cellular uptake mechanism of these rHDL-drug complexes.